Alzheimer’s Biomarker Development Hampered By ‘Limited’ Commercial Incentives

Eli Lilly executive suggests the public sector may need to come up with a solution to drive innovation if the private sector does not do so.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg

Development of biomarkers for Alzheimer’s disease is critically important to advancing innovative payment models for treatments as well as care models for patients with the disease, according to Eli Lilly & Co.’s Phyllis Ferrell, head of external engagement for Alzheimers and neurodegeneration.

But “biomarkers are an objective way of measuring response to therapy that we don’t have today,” Ferrell pointed out during...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet